Eli Lilly reaches deal to bring AI-developed drugs to global market
A drone view shows the Eli Lilly logo on the company’s office in San Diego, California, Nov. 21,…
Every Cure’s drug repurposing could change rare disease treatment
Dr. David Fajgenbaum, one of the founders of Every Cure, a nonprofit focused on drug repurposing. Courtesy of…
Menstrual products prices skyrocketing from inflation, tariffs
Always products are displayed on a shelf in a supermarket in Sarajevo, Bosnia and Herzegovina October 29, 2024. …
How CNBC Cures is bringing rare disease stories to a national audience
Last summer, my sister Becky approached me with an idea. She wanted my help building a platform at…
FDA approves high dose version of Novo Nordisk’s obesity drug Wegovy
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark,…
Eli Lilly’s obesity drug retatrutide clears late-stage diabetes trial
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike…
Stopping GLP-1s raises cardiovascular risks: study
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. Hollie Adams | Reuters…
Vertex kidney drug povetacicept succeeds in trial for IgAN
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston. Brian Snyder | Reuters…
Eli Lilly launches program to boost employer coverage of obesity drugs
Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the…
Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly
Novo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its…
What’s next for Novo Nordisk’s obesity drug CagriSema
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news…
Eli Lilly launches Zepbound obesity drug pen with one month of doses
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March…